- COMPOUNDS
-
The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein X is selected from (II) and (III), Y is selected from SO2NH, CONH, CH=N, CH2NH and CH=CH; R1-5 are each independently selected from H, OH, OR6, CO2H, C02R7, NO2, CN CONR8R9, CONHR10, CO2(CH2)nCO2R11, CO2(CH2)mO(CO)R12, CO2CHR13COR14, CONH(CH2)pCO2R15, CONH(CH2)qO(CO)R16, CONHCHRI7COR18; R6-18 are each independently hydrocarbyl; n, m, p and q are each independently 1, 2, 3 or 4; with the proviso that when X is phenyl, Y is CH=CH, R3 is OH and R1, R4 and R5 are H, R2 is other than COON. Further aspects of the invention relate to the use of such compounds in the preparation of a medicament for the treatment or prevention of transmissible spongiform encephalopathies (TSEs), and pharmaceutical compositions comprising the same.
- -
-
Page/Page column 38
(2010/02/14)
-
- Synthesis of analogues of Congo red and evaluation of their anti-prion activity
-
No cure as of yet exists for any of the transmissible spongiform encephalopathies. In this paper, we describe the synthesis of analogues of Congo red and evaluation against a cellular model of infection, the SMB (scrapie mouse brain) persistently infected cell line, for their ability to inhibit the infectivity of the abnormal form of prion protein (PrP-res). The compounds have also been tested for their ability to inhibit the polymerization of PrP C by PrP-res. A number of analogues showed inhibition of PrP-res infectivity at nanomolar concentrations. Several analogues show promise; the most active compound, 2a, inhibits the formation of PrP-res in SMB cells with an EC50 of 25-50 nM.
- Sellarajah, Shane,Lekishvili, Tamuna,Bowring, Claire,Thompsett, Andrew R.,Rudyk, Helene,Birkett, Christopher R.,Brown, David R.,Gilbert, Ian H.
-
p. 5515 - 5534
(2007/10/03)
-